Aardvark Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -2.52%
- Market cap
- $33.93M
- 21.89M shares
- Filings
- 120
Q3 2026
—Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−23.7% FY25 yoy
- $33.93M
- —
- —
- 0.6×
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $0 | reported |
Pharmaceutical preparations
Aardvark Therapeutics, Inc. is the 354th largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
APLMApollomics Inc.Fiscal 2024 figures———$37.6MVERUVeru Inc.———$36.1MTELOTelomir Pharmaceuticals, Inc.———$36.1MANVSAnnovis Bio, Inc.$0.0——$35.7MOSTXOS Therapies Inc———$35.3M
AARDAardvark Therapeutics, Inc. (this company)$0.0——$33.9M
NNVCNanoviricides, Inc.$0.0——$33.7MSCYXScynexis Inc$20.6M449.9%41.8%$32.9MPMNProMIS Neurosciences Inc.———$31.6MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Aardvark Therapeutics, Inc. · CIK 1774857 · Engraved from SEC EDGAR